Tzield (teplizumab), recognized as the world’s first and only targeted therapy for delaying the onset of type 1 diabetes, has received approval for use in the Boao Lecheng medical tourism pilot zone as a clinically urgently needed import drug. Developed by French pharmaceutical giant Sanofi, Tzield is indicated for use in adults and children aged 8 years and above to delay the progression of type 1 diabetes from stage 2 to stage 3.
Teplizumab, a monoclonal antibody (mAb) that targets CD3, has been shown to protect pancreatic islet β cells, thereby delaying the onset of type 1 diabetes for nearly three years.- Flcube.com
